Nanogrow is a pioneering startup in the development of biological therapies based on nanoantibodies, designed to transform the pharmaceutical sector. Its mission is to develop a new generation of biological drugs that offer the efficacy of traditional antibodies with the precision and safety of localized administration, significantly reducing side effects and increasing accessibility for a larger number of patients.

Nanoantibodies are the smallest known antibodies, with a simple structure and exceptional physicochemical stability. This robustness allows for specific formulation and administration, minimizing risks in undesired tissues. Due to their small size, nanoantibodies efficiently penetrate target tissues, specifically neutralizing the molecules responsible for each disease with high efficiency.

Its platform integrates camelid-derived nanoantibodies, synthetic libraries, biophysical, computational, and biochemical characterization, artificial intelligence, and galenic formulations. This cutting-edge technology enables us to identify and produce specific nanoantibodies for each disease, optimizing the development process and reducing costs. As a result, it offers innovative therapeutic solutions that can revolutionize disease treatment and position us as global leaders in this technology.